Halo garners support for PhII DMD study

Tiny Halo Therapeutics has rounded up $1.1 million from a dozen nonprofits to help set up a mid-stage study of its experimental drug for Duchenne muscular dystrophy. Halo, which has received all of its support so far from a pair of DMD patient groups, wants to launch a Phase II for HT-100, an oral drug designed to reduce fibrosis and promote healthy muscle fiber regeneration in DMD patients, in the second half of this year. Release

 

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.